Is AOD-9604 Legal in Florida? How to Access It Legally

What Is AOD-9604 and Why Does Its Legal Status Matter?

AOD-9604 is a synthetic peptide derived from amino acids 176 to 191 of the human growth hormone (hGH) molecule. Researchers isolated this fragment specifically because it appeared to stimulate lipolysis and inhibit lipogenesis without the insulin-resistance or IGF-1-elevating effects seen with full-length hGH. [Metabolic peptides that act on fat tissue without triggering IGF-1 pathways are rare.] That narrow pharmacological profile made it commercially interesting in the early 2000s, when the Australian company Metabolic Pharmaceuticals advanced it through Phase IIb clinical trials for obesity.

Because AOD-9604 was never approved by the FDA and has since landed on a federal restricted list for certain pharmacy types, patients and clinicians in Florida must understand exactly which legal doors remain open and which have closed.

The Monash University Clinical Trial Record

The most-cited human evidence comes from a Metabolic Pharmaceuticals-sponsored Phase IIb trial conducted at Monash University. That study enrolled approximately 300 participants with obesity and tested multiple oral doses over 12 weeks. The 1 mg/day group showed statistically significant fat loss compared with placebo, while higher doses did not outperform the 1 mg arm, suggesting a non-linear dose-response relationship. No serious adverse events were attributed to the peptide. The company did not proceed to Phase III, and no New Drug Application (NDA) was ever submitted to the FDA. Because the FDA has not reviewed a complete NDA, AOD-9604 has no approved indication, no approved dosage form, and no approved route of administration in the United States.

Why Physicians Still Prescribe It

Despite the lack of FDA approval, physicians operating under the "practice of medicine" doctrine retain legal authority to prescribe non-approved compounds when a compounding pharmacy produces them lawfully. The Federal Food, Drug, and Cosmetic Act (FD&C Act) Section 503A explicitly allows state-licensed compounding pharmacies to prepare drugs for individual patients based on a valid prescription, even if those drugs lack FDA approval, provided the compound does not appear on the FDA's list of drugs that are demonstrably unsafe or on the bulk-drug substances list restricted for 503B facilities. Section 503A pharmacies are not the same as 503B outsourcing facilities, and the two face very different federal rules.

Federal Regulatory Framework: FDA Bulk-Drug Lists and What They Mean

Understanding whether AOD-9604 is accessible legally requires separating two distinct federal lists that the FDA maintains under the FD&C Act.

The 503B Prohibition (2023 Update)

Section 503B of the FD&C Act governs "outsourcing facilities," which are large-scale compounding operations that may sell compounded drugs to healthcare providers without patient-specific prescriptions. These facilities can only use bulk drug substances that appear on an FDA-approved "positive list." AOD-9604 is not on that positive list. The FDA's 2023 guidance documents and related Federal Register notices made clear that peptides not on the approved 503B bulk-substance list, including AOD-9604, may not be compounded by outsourcing facilities. The FDA maintains its current 503B bulks list at the agency's compounding hub.

This means that any large compounding pharmacy operating as a registered 503B outsourcing facility cannot legally produce AOD-9604 for distribution in Florida or any other state.

The 503A Pathway and Its Limits

Section 503A pharmacies are traditional compounding operations that prepare drugs for specific patients under a prescription from a licensed practitioner. The FDA's authority over 503A pharmacies is more limited: these pharmacies must comply with state board of pharmacy rules and must not compound drugs that appear on the FDA's "503A prohibited list" (drugs removed from the market for safety reasons or those found to be essentially copies of approved drugs). AOD-9604 does not currently appear on the 503A prohibited list maintained under 21 U.S.C. 353a.

The practical consequence: a Florida-licensed 503A compounding pharmacy can, as of July 2025, prepare AOD-9604 for an individual patient if a licensed Florida physician writes a valid prescription. That window may not remain open indefinitely. The FDA has been progressively reviewing peptides for 503A bulk-substance classification, and AOD-9604 is among the substances under ongoing agency scrutiny.

DEA Schedule Status

AOD-9604 is not listed under any schedule of the Controlled Substances Act as of July 2025. It does not share a chemical structure with anabolic steroids, opioids, or other scheduled peptides such as BPC-157 analogs. Physicians do not need a DEA-X waiver or any special DEA registration to prescribe it. Standard state medical licensing and DEA registration for general practice are sufficient. DEA scheduling information is searchable through the DEA's Diversion Control Division database.

Florida State Law: What the State Adds (and Does Not Add)

Florida does not maintain a separate list of banned peptides beyond federal law. The Florida Board of Pharmacy, operating under Florida Statutes Chapter 465 and Florida Administrative Code Rule 64B16, requires that compounding pharmacies follow USP standards and that prescriptions for compounded drugs be based on a documented patient-specific medical need. Florida does not have a state-level AOD-9604-specific prohibition.

Florida's Medical Practice Act

The Florida Medical Practice Act (Chapter 458, Florida Statutes) grants licensed physicians broad authority to use their professional judgment in treating patients, including prescribing compounded medications not approved by the FDA. Florida Statute 458.331 sets the standards for physician practice and prescribing. A physician who prescribes AOD-9604 must document a legitimate clinical rationale in the patient's medical record, conduct an appropriate evaluation, and ensure the compounding pharmacy used holds an active Florida pharmacy permit.

Telehealth Prescribing in Florida

Florida's Telehealth Act (Section 456.47, Florida Statutes) permits licensed physicians to establish a patient-provider relationship and prescribe medications via telehealth, including compounded drugs, provided they meet the same standard of care as in-person visits. A Florida patient seeking AOD-9604 through a telehealth hormone clinic is operating within a legally recognized framework, as long as the prescribing physician holds an active Florida license and the dispensing pharmacy holds an active Florida permit.

Florida Board of Pharmacy Oversight

The Florida Board of Pharmacy can discipline pharmacies that compound drugs outside appropriate clinical guidelines or that fail to document individualized patient need. A compounding pharmacy that mass-produces AOD-9604 without patient-specific prescriptions, or that ships it to patients without a valid prescription on file, would be violating both state and federal law. Patients should verify that any pharmacy they use holds an active Florida Non-Resident or In-State Pharmacy permit, which is searchable through the Florida Department of Health licensure database.

How to Get AOD-9604 Legally in Florida: A Step-by-Step Path

Accessing AOD-9604 legally in Florida requires three things working together: a licensed physician who evaluates your clinical picture, a valid prescription, and a licensed 503A compounding pharmacy. None of these steps can be skipped.

Step 1: Find a Qualified Physician

The prescribing physician must hold an active Florida medical license (MD or DO). Board certification in endocrinology, obesity medicine, or internal medicine is relevant but not legally required. The physician must conduct an evaluation, which may occur in person or via telehealth, and must document why AOD-9604 is being prescribed for your specific clinical situation. A clinic that offers AOD-9604 without any evaluation or without maintaining a medical record is operating outside the standard of care and likely outside the law.

Step 2: The Clinical Evaluation

A legitimate evaluation for AOD-9604 typically includes a review of your weight history, prior weight-loss interventions, current medications, metabolic labs (fasting glucose, insulin, lipid panel, thyroid function), and any contraindications. Physicians who are familiar with peptide therapy often use AOD-9604 in patients who have not responded adequately to lifestyle modification alone and who are not candidates for, or have not tolerated, FDA-approved GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound). GLP-1 trials provide a useful benchmark: STEP-1 (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo (P<0.001). [1] AOD-9604 has no comparable Phase III dataset, which is one reason it is positioned as a compounded alternative rather than a first-line agent.

Step 3: Obtain a Valid Prescription

The prescription must identify the patient by name, include the physician's DEA number and Florida license number, specify the compound (AOD-9604), its dose, route, frequency, and quantity, and include a documented medical rationale. Prescriptions that are issued in bulk or that lack patient-specific documentation do not satisfy 503A requirements.

Step 4: Choose a Licensed 503A Compounding Pharmacy

The pharmacy must hold an active Florida permit or a Florida Non-Resident Pharmacy permit if located out of state. It should follow USP Chapter 795 (non-sterile) or USP Chapter 797 (sterile) standards depending on the dosage form, be accredited by PCAB (Pharmacy Compounding Accreditation Board) or its equivalent, and provide a certificate of analysis (COA) from an independent third-party laboratory confirming purity and potency of each batch. Injectable formulations of AOD-9604 require sterile compounding under USP 797 standards. USP 797 standards for sterile compounding are maintained at the United States Pharmacopeia.

The HealthRX medical team applies a four-gate framework when evaluating whether a patient is a reasonable candidate for compounded AOD-9604: (1) documented failure of lifestyle intervention for at least 6 months, (2) BMI <40 with metabolic comorbidity or BMI <35 without, where GLP-1 therapy is contraindicated or not tolerated, (3) normal or near-normal fasting IGF-1 to exclude growth hormone excess, and (4) prescription filled only through a PCAB-accredited 503A pharmacy with a current COA on file. Patients who do not meet all four gates are counseled toward FDA-approved alternatives first.

Clinical Evidence: What the Research Actually Shows

Human Trial Data

The most rigorous human data on AOD-9604 comes from the Metabolic Pharmaceuticals Phase IIb program. A 12-week randomized controlled trial published in data summarized in the National Library of Medicine's clinical trial registry tested oral doses ranging from 1 mg to 10 mg daily in adults with obesity. The 1 mg/day arm demonstrated statistically significant fat loss versus placebo with no clinically meaningful changes in blood glucose, insulin, or IGF-1. See the NLM clinical trials registry for AOD-9604 study records. The company's decision not to pursue Phase III trials means there are no long-term safety data (beyond 12 weeks) in humans.

Mechanistic Research

Animal studies published in peer-reviewed journals have examined how AOD-9604 stimulates lipolysis. Mechanisms identified include activation of beta-3 adrenergic receptors in adipose tissue and modulation of hypothalamic pathways involved in energy expenditure, without binding to the growth hormone receptor. A 2004 mechanistic study in the American Journal of Physiology examined the lipolytic properties of the C-terminal hGH fragment in rodent models. These animal data inform dosing rationales used in compounding but do not substitute for human Phase III evidence.

Absence of Long-Term Safety Data

The FDA's concern with peptides like AOD-9604 is not primarily toxicity (the Phase IIb trial reported a favorable safety profile) but rather the absence of the complete safety and efficacy dataset required for drug approval. Without a full NDA, the agency cannot guarantee product consistency, sterility standards, or long-term outcomes. Physicians prescribing AOD-9604 must disclose this evidence gap to patients as part of informed consent. FDA guidance on compounded drug safety is available at the agency's human drug compounding page.

Risks of Obtaining AOD-9604 Outside Legal Channels

Purchasing AOD-9604 from "research chemical" websites, overseas pharmacies, or any supplier that does not require a prescription is illegal and medically dangerous in Florida and across the United States. Products sold as "for research use only" are not manufactured under sterile conditions or pharmaceutical-grade quality controls. Independent laboratory testing of peptides purchased from online research vendors has found contamination, incorrect concentrations, and non-sterile preparations in a significant proportion of samples. A 2018 FDA warning letter campaign targeting research chemical distributors is documented in the FDA enforcement archives.

Florida Statute 499.03 prohibits the purchase, distribution, or dispensing of prescription drugs without a valid prescription. Violations can result in third-degree felony charges. The physician who prescribes AOD-9604 can be disciplined by the Florida Board of Medicine under Section 458.331 if the prescription lacks documented medical justification.

Comparing AOD-9604 to FDA-Approved Weight-Loss Agents

Patients considering AOD-9604 should understand where it sits relative to approved therapies. The FDA has approved several agents for chronic weight management, each with Phase III trial packages containing thousands of patients and multi-year follow-up data.

Semaglutide 2.4 mg (Wegovy) produced 14.9% mean weight loss at 68 weeks in STEP-1 (N=1,961) [1], while tirzepatide 15 mg (Zepbound) produced up to 20.9% mean weight loss at 72 weeks in SURMOUNT-1 (N=2,539). [2] These agents carry FDA approval, standardized manufacturing, and multi-year cardiovascular outcome data (SELECT trial for semaglutide). [3]

AOD-9604 has no Phase III data, no FDA approval, and no cardiovascular outcome trial. Its appropriate role, if any, is as a compounded adjunct in carefully selected patients under physician supervision, not as a replacement for approved therapy.

What Physicians and Regulatory Bodies Say

The Endocrine Society's clinical practice guidelines on obesity pharmacotherapy do not mention AOD-9604, reflecting its status outside the approved-drug mainstream. The Endocrine Society's 2023 obesity pharmacotherapy guidelines are available through the Journal of Clinical Endocrinology and Metabolism. The American Association of Clinical Endocrinology (AACE) similarly limits its pharmacotherapy recommendations to FDA-approved agents in its 2023 obesity algorithm. [4]

The FDA has stated directly that compounded drugs "are not FDA-approved and have not undergone FDA's review process to evaluate their safety, effectiveness, and quality." FDA Q&A on compounding safety, fda.gov. That statement applies to all compounded peptides, including AOD-9604.

A HealthRX board-certified physician reviewed this article and noted: "I tell patients that AOD-9604 may have a role in fat metabolism based on the Phase IIb data, but I only prescribe it through a PCAB-accredited 503A pharmacy, and I document the absence of Phase III data in the informed consent. If a patient is eligible for semaglutide or tirzepatide, those are my first recommendation. AOD-9604 is a second- or third-line consideration for patients with specific contraindications to approved agents."